Digital Delivery of Patient Education: A Case Study of Symptom Self-Management During Cancer Treatment
Digital Intervention for Gastrointestinal (GI) Cancer Patients: A Case Study on Enhancing Symptom Self-Management During Treatment
1 other identifier
interventional
110
1 country
1
Brief Summary
The increasing shift from face-to-face to online patient-clinician encounters in the healthcare system requires patients to be more involved in their medical care. This raises the urgent need to evaluate the extent to which proactive patients' self-care can be supported, particularly by informed telemedicine digital channels. Despite this imperative, research offering evidence-based instructional design of digital education remains surprisingly scarce. Embracing the framework of science education, which highlights the functional role of different knowledge types in educational processes, the current study seeks to evaluate an educational approach aimed at supporting cancer patients undergoing chemotherapy. Cancer treatment serves as an exemplar health condition, demanding daily self-management from patients. The objectives of our research are as follows: (1) To delineate the types of knowledge required for effective symptom management, active participation in one's healthcare, and judicious decision-making regarding emergency room (ER) visits, with a focus on mechanistic knowledge pertaining to the rationale for treatment and procedural knowledge concerning the treatment regimen. (2) To appraise the impact of a digital learning environment in contrast to traditional methods on patients' acquisition of mechanistic and procedural knowledge. (3) To identify how patients engage with the digital patient education environment aiming to outline leaning patterns. The investigators hypothesize that implementing digital education will enhance patients' understanding of both the 'why' (mechanistic) and 'how' (procedural) aspects of their treatment. Importantly, the investigators expect that mechanistic knowledge will be more impactful than procedural knowledge, leading to better symptom management and patient involvement, and ultimately reducing unnecessary visits to the ER.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2022
CompletedFirst Submitted
Initial submission to the registry
December 17, 2023
CompletedFirst Posted
Study publicly available on registry
January 2, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2024
CompletedJanuary 3, 2024
December 1, 2023
1.7 years
December 17, 2023
December 31, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Symptom self-management knowledge
Measured by performance accuracy in a cancer-specific knowledge test
The test will be conducted in two time-points of the study, Time 0 (pre) and Time 2 (after two months)
Secondary Outcomes (3)
Self-efficacy in symptom management
The questionnaire will be administered three times: Time 0 (pre) and Time 2 (after two months)
Confidence in decision making
The questionnaire will be administered in two time-points of the study, Time 0 (pre) and Time 2 (after two months)
Patients engagement while learning
on Time 2, namely about two weeks to four weeks after recruitment
Study Arms (2)
Educational intervention group
EXPERIMENTALControl group
NO INTERVENTIONInterventions
Patients assigned to the experimental group will learn about symptom self-management in a digital learning environment.
Eligibility Criteria
You may qualify if:
- Gastrointestinal (GI) cancer patients
- Chemotherapy session within a specific round of treatment, with eligible treatments including FOLFOX, FOLFIRINOX, and FLOT.
- Hebrew speakers.
You may not qualify if:
- Impaired or degraded cognitive capabilities that may hinder effective learning.
- Individuals who discontinue their treatments due to terminal advancement of their disease or death.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tel Aviv Universitylead
- Weizmann Institute of Sciencecollaborator
Study Sites (1)
Ichilov Hospital
Tel Aviv, 6423906, Israel
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
December 17, 2023
First Posted
January 2, 2024
Study Start
October 1, 2022
Primary Completion
June 1, 2024
Study Completion
November 1, 2024
Last Updated
January 3, 2024
Record last verified: 2023-12
Data Sharing
- IPD Sharing
- Will not share
upon request